BRIEF-Evelo Biosciences, Abdul Latif Jameel Health Announce Strategic Collaboration
BRIEF-Evelo Biosciences, Abdul Latif Jameel Health Announce Strategic Collaboration
* EVELO BIOSCIENCES & ABDUL LATIF JAMEEL HEALTH ANNOUNCE STRATEGIC COLLABORATION
* COLLABORATION TO DEVELOP AND COMMERCIALIZE EVELO’S LEAD INFLAMMATION PRODUCT CANDIDATE EDP1815 IN THE MIDDLE EAST, TURKEY, AND AFRICA
* THE COMPANY IS ALSO CONDUCTING A PHASE 2 CLINICAL TRIAL FOR EDP1815 IN PSORIASIS, AS WELL AS TWO TRIALS IN PATIENTS HOSPITALIZED WITH COVID-19
* TOGETHER, EVELO AND ABDUL LATIF JAMEEL HEALTH WILL WORK TO ADDRESS THE SIGNIFICANT DISPARITY IN ACCESS TO MEDICAL CARE IN THE FASTEST-GROWING POPULATIONS AND GROWTH ECONOMIES OF THE DEVELOPING WORLD
* UNDER THE TERMS OF THE AGREEMENT, EVELO RECEIVED AN UPFRONT PAYMENT AND EQUITY INVESTMENT
* EVELO WILL BE RESPONSIBLE FOR THE DEVELOPMENT AND MANUFACTURING OF EDP1815, WHILST ABDUL LATIF JAMEEL HEALTH WILL BE RESPONSIBLE FOR REGULATORY SUBMISSIONS AND COMMERCIALIZATION ACTIVITIES IN THE AGREED-UPON REGIONS
* EVELO AND ABDUL LATIF JAMEEL HEALTH WILL PARTICIPATE IN A 50:50
Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 23 (Reuters) - EVELO BIOSCIENCES INC :
* EVELO BIOSCIENCES & ABDUL LATIF JAMEEL HEALTH ANNOUNCE STRATEGIC COLLABORATION
* COLLABORATION TO DEVELOP AND COMMERCIALIZE EVELO’S LEAD INFLAMMATION PRODUCT CANDIDATE EDP1815 IN THE MIDDLE EAST, TURKEY, AND AFRICA
* THE COMPANY IS ALSO CONDUCTING A PHASE 2 CLINICAL TRIAL FOR EDP1815 IN PSORIASIS, AS WELL AS TWO TRIALS IN PATIENTS HOSPITALIZED WITH COVID-19
* TOGETHER, EVELO AND ABDUL LATIF JAMEEL HEALTH WILL WORK TO ADDRESS THE SIGNIFICANT DISPARITY IN ACCESS TO MEDICAL CARE IN THE FASTEST-GROWING POPULATIONS AND GROWTH ECONOMIES OF THE DEVELOPING WORLD
* UNDER THE TERMS OF THE AGREEMENT, EVELO RECEIVED AN UPFRONT PAYMENT AND EQUITY INVESTMENT
* EVELO WILL BE RESPONSIBLE FOR THE DEVELOPMENT AND MANUFACTURING OF EDP1815, WHILST ABDUL LATIF JAMEEL HEALTH WILL BE RESPONSIBLE FOR REGULATORY SUBMISSIONS AND COMMERCIALIZATION ACTIVITIES IN THE AGREED-UPON REGIONS
* EVELO AND ABDUL LATIF JAMEEL HEALTH WILL PARTICIPATE IN A 50:50
Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月23日電-EVELO Biosciences Inc：*EVELO Biosciences和Abdul Latif Jameel Health宣佈戰略合作*合作在中東、土耳其和非洲開發EVELO的主要候選炎症產品EDP1815並將其商業化*該公司還在進行EDP1815治療牛皮癬的第二階段臨牀試驗，以及兩項針對新冠肺炎住院患者的試驗*EVELO和Abdul Latif Jameel Health將共同努力解決發展中世界增長最快的人口和增長的經濟體在獲得醫療保健方面的嚴重差距*根據協議條款，EVELO收到預付款和股權投資*EVELO將負責EDP1815的開發和製造，而Abdul Latif Jameel Health將負責商定地區的監管提交和商業化活動*EVELO和Abdul Latif Jameel Health將參加A 50：50進一步的公司報道：(Reurs.Briefs@thomsonreurs.com；)
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧